von Bergwelt-Baildon M - Search Results

1

Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysis.

Rothe A, Claßen A, Carney J, Hallek M, Mellinghoff SC, Scheid C, Holtick U, von Bergwelt-Baildon M. Rothe A, et al. Eur J Haematol. 2020 Apr;104(4):291-298. doi: 10.1111/ejh.13372. Epub 2020 Jan 20. Eur J Haematol. 2020. PMID: 31856310

2

Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK, von Bergwelt-Baildon M, Debey S, Hallek M, Schultze JL. Beyer M, et al. Blood. 2005 Sep 15;106(6):2018-25. doi: 10.1182/blood-2005-02-0642. Epub 2005 May 24. Blood. 2005. PMID: 15914560 Free article.

3

Post-transplant immunotherapy: combining cancer vaccines with hematopoietic stem cell transplantation.

Holtick U, von Bergwelt-Baildon M. Holtick U, et al. Expert Rev Vaccines. 2009 May;8(5):519-23. doi: 10.1586/erv.09.24. Expert Rev Vaccines. 2009. PMID: 19397408 Free article. No abstract available.

4

Is physical exercise possible in patients with critical cytopenia undergoing intensive chemotherapy for acute leukaemia or aggressive lymphoma?

Elter T, Stipanov M, Heuser E, von Bergwelt-Baildon M, Bloch W, Hallek M, Baumann F. Elter T, et al. Int J Hematol. 2009 Sep;90(2):199-204. doi: 10.1007/s12185-009-0376-4. Epub 2009 Jul 24. Int J Hematol. 2009. PMID: 19629631 Clinical Trial.

5

The role of B cells in the pathogenesis of graft-versus-host disease.

Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. Shimabukuro-Vornhagen A, et al. Blood. 2009 Dec 3;114(24):4919-27. doi: 10.1182/blood-2008-10-161638. Epub 2009 Sep 11. Blood. 2009. PMID: 19749094 Free article. Review.

6

CCC meets ICU: redefining the role of critical care of cancer patients.

von Bergwelt-Baildon M, Hallek MJ, Shimabukuro-Vornhagen AA, Kochanek M. von Bergwelt-Baildon M, et al. BMC Cancer. 2010 Nov 8;10:612. doi: 10.1186/1471-2407-10-612. BMC Cancer. 2010. PMID: 21059210 Free PMC article.

7

Toll-like receptor 9 agonists as cancer therapeutics.

Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR. Holtick U, et al. Expert Opin Investig Drugs. 2011 Mar;20(3):361-72. doi: 10.1517/13543784.2011.553187. Epub 2011 Jan 22. Expert Opin Investig Drugs. 2011. PMID: 21254877 Review.

8

Potential of Toll-like receptor 9 agonists in combined anticancer immunotherapy strategies: synergy of PAMPs and DAMPs?

Holtick U, Klein-Gonzalez N, von Bergwelt-Baildon MS. Holtick U, et al. Immunotherapy. 2011 Mar;3(3):301-4. doi: 10.2217/imt.10.118. Immunotherapy. 2011. PMID: 21395370 No abstract available.

9

Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma.

Klein-González N, Holtick U, Fairfax K, Weihrauch MR, von Bergwelt-Baildon MS. Klein-González N, et al. Expert Rev Vaccines. 2011 Mar;10(3):295-8. doi: 10.1586/erv.11.6. Expert Rev Vaccines. 2011. PMID: 21434797 Free article.

10

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report.

Shimabukuro-Vornhagen A, Rothe A, Nogova L, Kochanek M, Scheid C, von Bergwelt-Baildon M. Shimabukuro-Vornhagen A, et al. J Med Case Rep. 2011 May 30;5:215. doi: 10.1186/1752-1947-5-215. J Med Case Rep. 2011. PMID: 21624109 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

360 results

Search Page

Filters